Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1958 2
1980 1
1985 2
1987 1
1991 2
1992 1
1993 2
1995 1
1998 5
1999 1
2000 2
2001 1
2002 1
2006 1
2007 1
2009 1
2010 1
2011 7
2012 1
2013 5
2014 2
2015 3
2016 4
2017 2
2018 1
2019 2
2020 1
2022 3
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

55 results

Results by year

Filters applied: . Clear all
Page 1
A biological classification of Huntington's disease: the Integrated Staging System.
Tabrizi SJ, Schobel S, Gantman EC, Mansbach A, Borowsky B, Konstantinova P, Mestre TA, Panagoulias J, Ross CA, Zauderer M, Mullin AP, Romero K, Sivakumaran S, Turner EC, Long JD, Sampaio C; Huntington's Disease Regulatory Science Consortium (HD-RSC). Tabrizi SJ, et al. Among authors: borowsky b. Lancet Neurol. 2022 Jul;21(7):632-644. doi: 10.1016/S1474-4422(22)00120-X. Lancet Neurol. 2022. PMID: 35716693 Review.
An orally available, brain penetrant, small molecule lowers huntingtin levels by enhancing pseudoexon inclusion.
Keller CG, Shin Y, Monteys AM, Renaud N, Beibel M, Teider N, Peters T, Faller T, St-Cyr S, Knehr J, Roma G, Reyes A, Hild M, Lukashev D, Theil D, Dales N, Cha JH, Borowsky B, Dolmetsch R, Davidson BL, Sivasankaran R. Keller CG, et al. Among authors: borowsky b. Nat Commun. 2022 Mar 3;13(1):1150. doi: 10.1038/s41467-022-28653-6. Nat Commun. 2022. PMID: 35241644 Free PMC article.
Safety and efficacy of laquinimod for Huntington's disease (LEGATO-HD): a multicentre, randomised, double-blind, placebo-controlled, phase 2 study.
Reilmann R, Anderson KE, Feigin A, Tabrizi SJ, Leavitt BR, Stout JC, Piccini P, Schubert R, Loupe P, Wickenberg A, Borowsky B, Rynkowski G, Volkinshtein R, Li T, Savola JM, Hayden M, Gordon MF; LEGATO-HD Study Group. Reilmann R, et al. Among authors: borowsky b. Lancet Neurol. 2024 Mar;23(3):243-255. doi: 10.1016/S1474-4422(23)00454-4. Epub 2024 Jan 24. Lancet Neurol. 2024. PMID: 38280392 Clinical Trial.
A PET-CT study on neuroinflammation in Huntington's disease patients participating in a randomized trial with laquinimod.
Roussakis AA, Gennaro M, Gordon MF, Reilmann R, Borowsky B, Rynkowski G, Lao-Kaim NP, Papoutsou Z, Savola JM, Hayden MR, Owen DR, Kalk N, Lingford-Hughes A, Gunn RN, Searle G, Tabrizi SJ, Piccini P. Roussakis AA, et al. Among authors: borowsky b. Brain Commun. 2023 Apr 3;5(2):fcad084. doi: 10.1093/braincomms/fcad084. eCollection 2023. Brain Commun. 2023. PMID: 37020532 Free PMC article.
Outreach, Screening, and Randomization of APOE ε4 Carriers into an Alzheimer's Prevention Trial: A global Perspective from the API Generation Program.
Walsh T, Duff L, Riviere ME, Tariot PN, Doak K, Smith M, Borowsky B, Lopez Lopez C, Arratia PC, Liu F, Scholten I, Gordon D, Arbuckle J, Graf A, Quinn M, Ricart J, Langbaum JB. Walsh T, et al. Among authors: borowsky b. J Prev Alzheimers Dis. 2023;10(3):453-463. doi: 10.14283/jpad.2023.27. J Prev Alzheimers Dis. 2023. PMID: 37357285 Free PMC article. Clinical Trial.
A Computational Cognitive Biomarker for Early-Stage Huntington's Disease.
Wiecki TV, Antoniades CA, Stevenson A, Kennard C, Borowsky B, Owen G, Leavitt B, Roos R, Durr A, Tabrizi SJ, Frank MJ. Wiecki TV, et al. Among authors: borowsky b. PLoS One. 2016 Feb 12;11(2):e0148409. doi: 10.1371/journal.pone.0148409. eCollection 2016. PLoS One. 2016. PMID: 26872129 Free PMC article.
55 results